Pharma Deals Review, Vol 2007, No 80 (2007)

Font Size:  Small  Medium  Large

GlaxoSmithKline Further Improves its Biologics Capabilities

Business Review Editor

Abstract


GlaxoSmithKline (GSK) has entered into a US$2.1 B worldwide co-development agreement with Genmab to commercialize its most advanced unpartnered fully human monoclonal antibody HuMax-CD20™ (ofatumumab).

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.